La Revue de medecine interne · 2005
[Proteasome inhibitors].
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alexandre J
Аннотация
INTRODUCTION: Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.
EXEGESIS: Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use. As single agent, bortezomib displays antitumoral effects in refractory multiple myeloma and mantle cell lymphoma but has only modest activity in solid tumors. Preclinical data suggest that bortezomib could enhance antitumor activity of cytotoxics.
CONCLUSION: Proteasome inhibition is a promising therapeutic pathway, especially in lymphoid malignancies.
EXEGESIS: Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use. As single agent, bortezomib displays antitumoral effects in refractory multiple myeloma and mantle cell lymphoma but has only modest activity in solid tumors. Preclinical data suggest that bortezomib could enhance antitumor activity of cytotoxics.
CONCLUSION: Proteasome inhibition is a promising therapeutic pathway, especially in lymphoid malignancies.
Предметные рубрики MeSH
AdenocarcinomaAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBoronic AcidsBortezomibCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDexamethasoneDocetaxelDrug Therapy, CombinationFemaleGraft vs Host ReactionHumansKidney NeoplasmsLung NeoplasmsLymphoma, Mantle-CellMaleMiceMultiple MyelomaProstatic NeoplasmsProtease InhibitorsProteasome InhibitorsPyrazinesTaxoidsTime FactorsTreatment OutcomeTumor Cells, Cultured